Ritodrine hydrochloride: A betamimetic agent for use in preterm labor: I. pharmacology, clinical history, administration, side effects, and safety

Tom P. Barden, John B. Peter, Irwin R. Merkatz

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Ritodrine hydrochloride has become the first drug approved in the United States specifically for use in preterm labor. The drug is a β-sympathomimetic agent with predominant effects upon β<sup>2</sup>receptors of the uterus. In this report, the pharmacology, distribution, disposition, and excretion are briefly reviewed. Recommendations for selecting patients most likely to benefit from ritodrine are given, together with the dosage and administration schedules that have been found most effective. Although this drug is not without side effects, it has been more thoroughly evaluated in prospective double-blind controlled trials than any of the other agents commonly used in preterm labor. In comparison with these agents, it seems relatively safe and the side effects are usually well tolerated. Part 2 of the paper discusses the evidence for efficacy.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalObstetrics and Gynecology
Volume56
Issue number1
StatePublished - 1980
Externally publishedYes

Fingerprint

Ritodrine
Adrenergic beta-Agonists
Clinical Pharmacology
Premature Obstetric Labor
Safety
Pharmaceutical Preparations
Sympathomimetics
Uterus
Appointments and Schedules
Pharmacology

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

@article{4317298f03dd4943ada8baae8a8efc39,
title = "Ritodrine hydrochloride: A betamimetic agent for use in preterm labor: I. pharmacology, clinical history, administration, side effects, and safety",
abstract = "Ritodrine hydrochloride has become the first drug approved in the United States specifically for use in preterm labor. The drug is a β-sympathomimetic agent with predominant effects upon β2receptors of the uterus. In this report, the pharmacology, distribution, disposition, and excretion are briefly reviewed. Recommendations for selecting patients most likely to benefit from ritodrine are given, together with the dosage and administration schedules that have been found most effective. Although this drug is not without side effects, it has been more thoroughly evaluated in prospective double-blind controlled trials than any of the other agents commonly used in preterm labor. In comparison with these agents, it seems relatively safe and the side effects are usually well tolerated. Part 2 of the paper discusses the evidence for efficacy.",
author = "Barden, {Tom P.} and Peter, {John B.} and Merkatz, {Irwin R.}",
year = "1980",
language = "English (US)",
volume = "56",
pages = "1--6",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Ritodrine hydrochloride

T2 - A betamimetic agent for use in preterm labor: I. pharmacology, clinical history, administration, side effects, and safety

AU - Barden, Tom P.

AU - Peter, John B.

AU - Merkatz, Irwin R.

PY - 1980

Y1 - 1980

N2 - Ritodrine hydrochloride has become the first drug approved in the United States specifically for use in preterm labor. The drug is a β-sympathomimetic agent with predominant effects upon β2receptors of the uterus. In this report, the pharmacology, distribution, disposition, and excretion are briefly reviewed. Recommendations for selecting patients most likely to benefit from ritodrine are given, together with the dosage and administration schedules that have been found most effective. Although this drug is not without side effects, it has been more thoroughly evaluated in prospective double-blind controlled trials than any of the other agents commonly used in preterm labor. In comparison with these agents, it seems relatively safe and the side effects are usually well tolerated. Part 2 of the paper discusses the evidence for efficacy.

AB - Ritodrine hydrochloride has become the first drug approved in the United States specifically for use in preterm labor. The drug is a β-sympathomimetic agent with predominant effects upon β2receptors of the uterus. In this report, the pharmacology, distribution, disposition, and excretion are briefly reviewed. Recommendations for selecting patients most likely to benefit from ritodrine are given, together with the dosage and administration schedules that have been found most effective. Although this drug is not without side effects, it has been more thoroughly evaluated in prospective double-blind controlled trials than any of the other agents commonly used in preterm labor. In comparison with these agents, it seems relatively safe and the side effects are usually well tolerated. Part 2 of the paper discusses the evidence for efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0018941263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018941263&partnerID=8YFLogxK

M3 - Article

C2 - 6104316

AN - SCOPUS:0018941263

VL - 56

SP - 1

EP - 6

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -